Full Generic Medicine Info
Dosage/Direction for Use

Hypertension, Angina pectoris
Adult: 0.5-2 mg daily.
2nd and 3rd ° AV block; sinus bradycardia; uncontrolled heart failure; bronchospasm or asthma, metabolic acidosis, severe peripheral arterial disease, phaeochromocytoma.
Special Precautions
1st ° AV block. May mask symptoms of hyperthyroidism and hypoglycaemia. May unmask myasthenia gravis. May aggravate psoriasis. Gradual withdrawal over 1-2 wk is advisable otherwise, it may result in angina, MI, ventricular arrhythmias and death. Pregnancy and lactation.
Adverse Reactions
Bradycardia; hypotension; heart failure, heart block; bronchospasm; fatigue; coldness of extremities; pneumonitis; pulmonary and retroperitoneal fibrosis; pleurisy; CNS effects; myopathies; GI disturbances; skin rash; pruritus; reversible alopoecia; lupus-like syndrome; male impotence; sclerosing peritonitis; paraesthesias; peripheral neuropathy; muscle cramps; haematological reactions.
Drug Interactions
Drugs that cause hypotension; NSAIDs; other cardiac depressants; sotalol; digoxin; insulin and oral hypoglycaemics; sympathomimetics; ACE inhibitors; calcium-channel blockers, verapamil. Anaesthetics that cause myocardial depression (e.g. ether, cyclopropane, trichloroethylene).
Potentially Fatal: Increased risk of withdrawal HTN with clonidine. (Withdraw several days before slowly withdrawing clonidine).
Lab Interference
Changes in blood concentrations of triglycerides, glucose and cholesterol.
Bopindolol is a non-cardioselective β-blocker with some intrinsic sympathomimetic activity.
CIMS Class
ATC Classification
C07AA17 - bopindolol ; Belongs to the class of non-selective beta-blocking agents. Used in the treatment of cardiovascular diseases.
Disclaimer: This information is independently developed by CIMS based on bopindolol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in